MedPath

Maitenance therapy with bortezomib for multiple myeloma after autologus stem cell transplantatio

Not Applicable
Conditions
multiple myeloma
Registration Number
JPRN-UMIN000007188
Lead Sponsor
niversity Of Tokyo Hospital, Department of Hematology and Oncology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

1. Allergy for Bortezomib, mannitol, and boron. 2. A woman during pregnancy or potential pregnancy. 3. Patients who cannot stop drugs or therapy restricted in this trial. 4. Patients who are recoginized as inadaptable for this trial.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath